Janssen strikes licensing deal for investigational Alzheimer's treatment

Janssen Pharmaceuticals (JNJ +0.6%) inks a new development and commercialization deal with Finland's Orion Corp. for the latter's alpha-2c adrenoceptor antagonists including ORM-12741.

Orion gets a $31M upfront payment and is eligible for milestone payments and royalties — the company will use the upfront cash to help fund the Phase 2a study of ORM-12741.

ORM-12741 (which Janssen will have the right to commercialize outside of Europe) is being tested as a possible treatment for "the cognitive and behavioral symptoms related to Alzheimer's." (PR)

From other sites
Comments (3)
  • maddynuke
    , contributor
    Comments (333) | Send Message
    Note that Janseen Pharma is NOT JNJ!!!!!
    JNJ=Johnson and Johnson.


    Stupid mistake. Don't be confused!
    20 Dec 2013, 03:27 PM Reply Like
  • 21thomas99
    , contributor
    Comments (411) | Send Message
    What mistake are you referencing? Janssen Pharma is a subsidiary of JNJ. Ergo, no mistake was made.
    20 Dec 2013, 03:55 PM Reply Like
  • Punasan
    , contributor
    Comments (2) | Send Message
    Please check http://www.janssen.com it clearly says.
    22 Dec 2013, 12:47 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs